Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Alzheimer'S Research & Therapy|August 14, 2016
Older patients are still under-represented in clinical trials of Alzheimer's diseaseRita Banzi, Paolo Camaioni, Mauro Tettamanti, et al.
European Journal of Clinical Pharmacology|July 25, 2007
New antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approvalVittorio Bertele', Alessandro Assisi, Valeria Di Muzio, et al.
Pharmacoeconomics|June 20, 2008
Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in EuropeBjörn Wettermark, Brian Godman, Karolina Andersson, et al.
European Journal of Clinical Pharmacology|May 29, 2007
Haematological anticancer drugs in Europe: any added value at the time of approval?Vittorio Bertele', Rita Banzi, Filippo Capasso, et al.
European Journal of Internal Medicine|September 10, 2014
Fostering EMA's transparency policyRita Banzi, Vittorio Bertele', Jacques Demotes-Mainard, et al.
Journal of Clinical and Experimental Hepatology|September 14, 2019
New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled TrialsValentina Pecoraro, Rita Banzi, Elisabetta Cariani, et al.
Trials|August 3, 2017
Barriers to the conduct of randomised clinical trials within all disease areasSnezana Djurisic, Ana Rath, Sabrina Gaber, et al.
Trials|September 15, 2017
Specific barriers to the conduct of randomised clinical trials on medical devicesEdmund A M Neugebauer, Ana Rath, Sunya-Lee Antoine, et al.
Trials|September 13, 2017
Evidence-based practice within nutrition: what are the barriers for improving the evidence and how can they be dealt with?Martine Laville, Berenice Segrestin, Maud Alligier, et al.
Pageof 4